Vascular endothelial growth factor (VEGF) and its receptors in tumor-bearing dogs

被引:56
作者
Scheidegger, P
Weiglhofer, W
Suarez, S
Kaser-Hotz, B
Steiner, R
Ballmer-Hofer, K
Jaussi, R [1 ]
机构
[1] Univ Zurich, Inst Med Radiobiol, CH-5232 Villigen, Switzerland
[2] Paul Scherrer Inst, CH-5232 Villigen, Switzerland
[3] Univ Zurich, Dept Vet Surg, CH-8057 Zurich, Switzerland
[4] Univ Zurich Hosp, Cent Biol Lab, CH-8091 Zurich, Switzerland
关键词
angiogenesis; chorio-allantoic membrane; disease models; dogs; neovascularization; VEGF receptor;
D O I
10.1515/BC.1999.187
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular biology of the angiogenic growth factor, vascular endothelial growth factor (VEGF), has been studied in the dog. All major isoforms of VEGF are present in the dog. The amino acid sequences are identical between human and dog in the loop regions that are responsible for receptor binding. Accordingly, the VEGF receptors of dogs and humans are very similar and perm it functional exchange of the growth factor. Here we show that canine VEGF activates human endothelial cells to the same extent as human VEGF, Similarly, the two proteins display identical cell binding properties, The VEGF receptor 1 (Flt-1) shows the same alternative splicing in humans and dogs and is overexpressed in the majority of tumors in both species, VEGF occurs also in canine tumors in similar relative quantities as in human malignancies, Based on the literature and our study we suggest that the molecular biology and the function of the VEGF signaling system are virtually identical in humans and canines and in healthy as well as in disease conditions.
引用
收藏
页码:1449 / 1454
页数:6
相关论文
共 21 条
[1]  
Barleon B, 1997, CANCER RES, V57, P5421
[2]  
Christinger HW, 1996, PROTEINS, V26, P353, DOI 10.1002/(SICI)1097-0134(199611)26:3<353::AID-PROT9>3.0.CO
[3]  
2-E
[4]  
CLERC C, 1998, THESIS U ZURICH
[5]   A COMPREHENSIVE SET OF SEQUENCE-ANALYSIS PROGRAMS FOR THE VAX [J].
DEVEREUX, J ;
HAEBERLI, P ;
SMITHIES, O .
NUCLEIC ACIDS RESEARCH, 1984, 12 (01) :387-395
[6]  
FERRARA N, 1997, TUMOUR ANGIOGENESIS, P1
[7]   Tumor induction of VEGF promoter activity in stromal cells [J].
Fukumura, D ;
Xavier, R ;
Sugiura, T ;
Chen, Y ;
Park, EC ;
Lu, NF ;
Selig, M ;
Nielsen, G ;
Taksir, T ;
Jain, RK ;
Seed, B .
CELL, 1998, 94 (06) :715-725
[8]   Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice [J].
Hiratsuka, S ;
Minowa, O ;
Kuno, J ;
Noda, T ;
Shibuya, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9349-9354
[9]   The transcriptional program in the response of human fibroblasts to serum [J].
Iyer, VR ;
Eisen, MB ;
Ross, DT ;
Schuler, G ;
Moore, T ;
Lee, JCF ;
Trent, JM ;
Staudt, LM ;
Hudson, J ;
Boguski, MS ;
Lashkari, D ;
Shalon, D ;
Botstein, D ;
Brown, PO .
SCIENCE, 1999, 283 (5398) :83-87
[10]   INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR ACTIVITY BY AN ENDOGENOUSLY ENCODED SOLUBLE RECEPTOR [J].
KENDALL, RL ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10705-10709